MD Share Price | Pediatrix Medical Group, Inc. Stock Analysis & Recommendation

Q: What does Pediatrix Medical Group, Inc. do?

Overview:Pediatrix Medical Group, Inc. is a provider of physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 458 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 21 Million (Quarterly Results - Mar 2025) Market-cap: USD 1,152.00 Million (Micro Cap)Key Metrics:P/E: 8.00 Debt Equity: 0.51 Return on Equity: 19.10% Price to Book: 1.46 Contact Details:Address: 1301 Concord Ter, SUNRISE FL: 33323-2843 Tel: 1 954 3840175 Fax: 1 954 8389961 Website: https://www.mednax.com/

Q: Is Pediatrix Medical Group, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Pediatrix Medical Group, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish MACD readings on both weekly and monthly time frames, and a bullish daily moving average. However, the weekly RSI is bearish, indicating some short-term weakness. The KST is bullish on both weekly and monthly bases, while the Bollinger Bands show a mildly bullish trend in both time frames. Dow Theory presents a mixed view with a mildly bearish weekly stance but a mildly bullish monthly outlook. In terms of performance, Pediatrix has outperformed the S&P 500 year-to-date with a return of 26.45% compared to the S&P's 12.22%, and over the past year, it has returned 52.76% versus the S&P's 17.14%. However, over longer periods, the stock has underperformed significantly. Overall, the bullish trend is supported by several indicators, despite some mixed signals in the short term.

Q: Is Pediatrix Medical Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Pediatrix Medical Group, Inc. has moved from attractive to very attractive, indicating a positive shift in its perceived value. Based on the current metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, all of which suggest that the stock is trading at a discount compared to its earnings growth potential.In comparison to peers, Pediatrix Medical Group has a lower P/E ratio than Hims & Hers Health, Inc., which stands at 54.76, and a more favorable EV to EBITDA ratio than RadNet, Inc., which is at 26.07. This further reinforces the notion that Pediatrix is undervalued relative to its industry peers. Additionally, the company's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 25.38% compared to the S&P 500's 13.30%, highlighting its strong performance in the market.

Results Declared: Pediatrix Medical Group, Inc. has declared results on 05 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

281.57 k

Shareholding (Mar 2026)

FII

7.83%

Held by 118 FIIs

DII

31.32%

Held by 73 DIIs

Promoter

0.00%

How big is Pediatrix Medical Group, Inc.?

22-Jun-2025

As of Jun 18, Pediatrix Medical Group, Inc. has a market capitalization of 1,152.00 million and reported net sales of 1,976.18 million with a net profit of -82.37 million over the latest four quarters. Shareholder's funds are 764.94 million, and total assets amount to 2,152.70 million.

View full answer

What does Pediatrix Medical Group, Inc. do?

22-Jun-2025

Pediatrix Medical Group, Inc. provides physician services specializing in newborn, maternal-fetal, and pediatric subspecialty care. As of March 2025, it reported net sales of $458 million and a net profit of $21 million, with a market cap of $1.15 billion.

View full answer

Who are in the management team of Pediatrix Medical Group, Inc.?

22-Jun-2025

As of March 2022, the management team of Pediatrix Medical Group, Inc. includes Mr. Guy Sansone (Independent Chairman), Mr. Manuel Kadre (Lead Independent Director), Dr. Roger Medel, Ms. Karey Barker, Dr. Waldemar Carlo, and Mr. Paul Gabos, all serving as directors. They are responsible for the company's strategic direction and governance.

View full answer

Is Pediatrix Medical Group, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Pediatrix Medical Group, Inc. shows a bullish trend supported by positive MACD and KST readings, despite a bearish weekly RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over the past year.

View full answer

Is Pediatrix Medical Group, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Pediatrix Medical Group, Inc. is considered very attractive and undervalued, with a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, outperforming peers and the S&P 500 with a year-to-date return of 25.38%.

View full answer

Compare Pediatrix Medical Group, Inc. with Similar Stocks

OPKO Health, Inc.Celldex Therapeutics, Inc.Hims & Hers Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Profit of 89.32%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD 244.56 MM
ROCE(HY) Highest at 14.27%
INTEREST COVERAGE RATIO(Q) Highest at 755.9

With ROCE of 16.57%, it has a risky valuation with a 1.35 Enterprise value to Capital Employed

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,618 Million (Small Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.12

Return on Equity

21.04%

Price to Book

1.87

Revenue and Profits:

Net Sales:

476 Million

(Quarterly Results - Mar 2026)

Net Profit:

30 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

12.54%

6 Months

7.2%

1 Year

62.81%

2 Years

176.59%

3 Years

71.23%

4 Years

25.65%

5 Years

-26.76%

Pediatrix Medical Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-3.03%

EBIT Growth (5y)

3.94%

EBIT to Interest (avg)

3.79

Debt to EBITDA (avg)

2.77

Net Debt to Equity (avg)

0.51

Sales to Capital Employed (avg)

1.35

Tax Ratio

1.59%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

13.11%

ROE (avg)

14.52%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.87

EV to EBIT

7.47

EV to EBITDA

6.82

EV to Capital Employed

1.77

EV to Sales

0.90

PEG Ratio

0.24

Dividend Yield

ROCE (Latest)

23.74%

ROE (Latest)

21.04%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 75 Schemes (60.77%)

Foreign Institutions

Held by 118 Foreign Institutions (7.83%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -3.56% vs 0.18% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -12.17% vs -53.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "476.20",
          "val2": "493.80",
          "chgp": "-3.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "52.70",
          "val2": "60.30",
          "chgp": "-12.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.30",
          "val2": "8.70",
          "chgp": "-4.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.90",
          "val2": "-5.90",
          "chgp": "16.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "29.60",
          "val2": "33.70",
          "chgp": "-12.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "97.80%",
          "val2": "110.70%",
          "chgp": "-1.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -4.92% vs 0.92% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 266.90% vs -64.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,913.80",
          "val2": "2,012.90",
          "chgp": "-4.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "252.90",
          "val2": "215.90",
          "chgp": "17.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "36.00",
          "val2": "40.70",
          "chgp": "-11.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-22.30",
          "val2": "-242.70",
          "chgp": "90.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "165.40",
          "val2": "-99.10",
          "chgp": "266.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "120.70%",
          "val2": "91.30%",
          "chgp": "2.94%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

476.20

493.80

-3.56%

Operating Profit (PBDIT) excl Other Income

52.70

60.30

-12.60%

Interest

8.30

8.70

-4.60%

Exceptional Items

-4.90

-5.90

16.95%

Consolidate Net Profit

29.60

33.70

-12.17%

Operating Profit Margin (Excl OI)

97.80%

110.70%

-1.29%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -3.56% vs 0.18% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -12.17% vs -53.00% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,913.80

2,012.90

-4.92%

Operating Profit (PBDIT) excl Other Income

252.90

215.90

17.14%

Interest

36.00

40.70

-11.55%

Exceptional Items

-22.30

-242.70

90.81%

Consolidate Net Profit

165.40

-99.10

266.90%

Operating Profit Margin (Excl OI)

120.70%

91.30%

2.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -4.92% vs 0.92% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 266.90% vs -64.07% in Dec 2024

All Annual Results

Company CV

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc.

Pharmaceuticals & Biotechnology

MEDNAX, Inc is a provider of physician services, including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. The Company's national network consist of physicians, including over physicians providing neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. It also has affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. Its network also included other pediatric subspecialists, physicians providing pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat and pediatric ophthalmology services.

Company Coordinates

Company Details

1301 Concord Ter , SUNRISE FL : 33323-2843

Tel: 1 954 38401751 954 3840175

https://www.mednax.com/

Registrar Details